Newsfeeds - Spark Newswire

5 minute read

This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday

Today, 5:16 PM

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending on January 17, 2023.

16 minute read

Earnings Scheduled For May 9, 2022

By Benzinga Insights

Today, 5:16 PM

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

ACM

1 minute read

Earnings

Earnings Outlook For Otonomy

By Benzinga Insights

Today, 5:16 PM

Otonomy (NASDAQ:OTIC) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Otonomy will report an earnings per share (EPS) of $-0.20.

OTIC

1 minute read

Oppenheimer Maintains Outperform on Otonomy, Raises Price Target to $6

By Benzinga Newsdesk

Today, 5:16 PM

Oppenheimer analyst Francois Brisebois maintains Otonomy (NASDAQ:OTIC) with a Outperform and raises the price target from $5 to $6.

OTIC

2 minute read

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus’ COVID-19 Vaccine Trial Data, FDA Rejects Teva’s Schizophrenia Med, Otonomy Aces Hearing Loss Study

By Vandana Singh

Today, 5:16 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ALVR

1 minute read

Earnings

Otonomy: Q4 Earnings Insights

By Benzinga Insights

Today, 5:16 PM

Otonomy (NASDAQ:OTIC) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Otonomy missed estimated earnings by 11.11%, reporting an EPS of $-0.2 versus an estimate of $-0.18.

OTIC

10 minute read

Earnings Scheduled For February 28, 2022

By Benzinga Insights

Today, 5:16 PM

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.

AAON

1 minute read

Otonomy Completes Enrollment In Phase 2 Clinical Trial Of OTO-313 In Tinnitus

By Benzinga Newsdesk

Today, 5:16 PM

Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 2 clinical trial of

OTIC

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

Today, 5:16 PM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL

1 minute read

Otonomy Q3 EPS $(0.19) Misses $(0.18) Estimate

By Benzinga Newsdesk

Today, 5:16 PM

Otonomy (NASDAQ:OTIC) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 13.64 percent increase over losses of $(0.22) per share from the same

OTIC